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ABSTRACT
Interleukin 17B (IL-17B) is a pro-inflammatory cytokine that belongs to the IL-
17 cytokines family and binds to IL-17 receptor B (IL-17RB). Here we found that high 
expression of IL-17B and IL-17RB is associated with poor prognosis in patients with 
breast cancer and that IL-17B expression upregulation is specifically associated with 
poorer survival in patients with basal-like breast cancer. We thus focused on IL-17B 
role in breast cancer by using luminal and triple negative (TN)/basal-like tumor cell 
lines. We found that IL-17B induces resistance to conventional chemotherapeutic 
agents. In vivo, IL-17B induced resistance to paclitaxel and treatment with an anti-
IL-17RB neutralizing antibody completely restored breast tumor chemosensitivity, 
leading to tumor shrinkage. We next focused on the signaling pathways activated in 
human breast cancer cell lines upon incubation with IL-17B. We observed that IL-17B 
induces ERK1/2 pathway activation, leading to upregulation of anti-apoptotic proteins 
of the BCL-2 family. IL-17B-induced chemoresistance was completely abolished by 
incubation with PD98059, an inhibitor of the MAPK/ERK pathway, indicating that the 
ERK pathway plays a crucial role. Altogether our results emphasize the role of the IL-
17B/IL-17RB signaling pathway in breast tumors and identify IL-17B and its receptor 
as attractive therapeutic targets for potentiating breast cancer chemotherapy. 
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INTRODUCTION
Tumor development is regulated by many different 
factors that influence cancer cell proliferation, cell death 
resistance and dissemination within the organism [1]. 
Particularly, it is now well established that inflammation-
associated factors, such as chemokines and cytokines 
present within the tumor microenvironment, are crucial 
for modulating cancer progression and resistance to 
treatments [2]. Among the inflammatory mediators, a 
growing body of evidence emphasizes the contribution 
of the IL-17 cytokine family in malignant diseases. The 
IL-17 family includes six members (IL-17A to IL-17F) 
with different homology and functions [3]. IL-17A and 
IL-17F are the closest members, with 50% homology. 
These cytokines exert their activities through binding to 
IL-17 receptor (IL-17R) family members (IL-17RA to IL-
17RE) that function as homo-or heterodimer complexes 
[4]. IL-17A is the prototypic member of the IL-17 family. 
It is predominantly produced by T helper 17 cells, a 
subset of CD4+ T cells. Binding of IL-17A to its receptor 
IL-17RA/RC leads to the production of cytokines and 
chemokines, such as TNF-α, IL-6, CXCL8 and CXCL1, 
that are involved in mechanisms of host defenses against 
extracellular bacterial and fungal infections [5]. Over-
production of IL-17A has also been associated with 
chronic inflammatory disorders and autoimmune diseases 
[4, 6, 7]. Moreover, IL-17A has been detected in several 
human tumors, where it has been associated with pro-
tumorigenic effects, and particularly with resistance to 
cancer therapies, by acting on cancer cells and also on the 
tumor microenvironment  [8, 9].
Other members of the IL-17 and IL-17R families 
are expressed in various tissues at low levels. Although 
their involvement in pathological processes remains to 
be fully characterized, several experimental findings 
strongly suggest a role for the IL-17B/IL-17RB pathway 
in tumorigenesis. Indeed, the IL-17RB locus is a common 
site of retroviral integration in murine myeloid leukemia. 
The resulting IL-17RB expression upregulation in 
leukemic cells suggests a pro-oncogenic role for this 
receptor [10]. In humans, IL-17RB overexpression has 
been reported in a subset of adult patients with acute T-cell 
leukemia. Moreover, IL-17RB overexpression in HTLV-1 
transformed T cells contributes to cell growth and survival 
via the NF-κB pathway [11]. In solid tumors, amplified IL-
17B/IL-17RB signaling is critical for breast and pancreatic 
tumorigenesis and elevated IL-17RB expression has been 
associated with the shortest survival rates in patients 
with breast or pancreatic cancer. Specifically, IL-17B 
produced by breast cancer cells promotes anti-apoptotic 
signaling and tumor survival through activation of the 
NF-κB pathway [12]. In pancreatic cancer cell lines, 
IL-17B activates the ERK1/2 pathway and induces the 
production of the chemokines CCL20, CXCL1, IL-8 
and TFF1. Following the activation of such chemokines, 
IL-17B promotes the recruitment of macrophages that, 
in turn, favors cancer cell survival and invasion as well 
as the recruitment of endothelial cells with vasculogenic 
potential, thus stimulating tumor angiogenesis [13]. 
Thus, besides IL-17A, IL-17B also could play an 
important role in tumor progression through its binding to 
IL-17RB and might represent a potential therapeutic target 
in solid tumors, such as breast and pancreatic cancers. As 
IL-17B role in the response to anti-cancer therapies has not 
been precisely investigated yet, we decided to explore IL-
17B function in breast tumor response to chemotherapy.
RESULTS 
IL-17B overexpression in breast cancer is 
associated with poor prognosis
Although high IL-17RB expression was previously 
associated with poor prognosis in patients with breast 
cancer [12, 14], the prognostic value of IL-17B per se has 
never been investigated.  We thus evaluated the expression 
of IL-17B and IL-17RB by real-time quantitative PCR 
in biopsies from a cohort of patients with breast cancer 
(n = 143) (Supplementary Table 1) and 10 years of follow-
up. We then assessed the correlation between IL-17B and 
IL-17RB expression and patient survival.  High and low 
IL-17B or IL-17RB expression levels were defined based 
on a cutoff value calculated from the internal standard 
curve. As indicated by the Kaplan-Meier survival analysis 
in Figure 1A and 1B, high IL-17B expression tended 
to be associated with reduced overall survival (OS) 
(p =  0.05), but not disease-free survival (DFS) (p =  0.15). 
Conversely, high IL-17RB levels were associated with 
reduced DFS (p = 0.03). Moreover, OS (p = 0.016) and 
DFS (p = 0.029) were significantly reduced in patients 
with cancers in which both IL-17B and IL-17RB were 
overexpressed compared with patients with cancers where 
only one was upregulated or where both molecules were 
expressed at low level (Figure 1C). Although these data 
must be confirmed in a larger cohort of patients, they 
indicate that in addition to IL-17RB, IL-17B expression 
level also could influence breast cancer prognosis.
To further refine the prognostic value of IL-17B per 
se, we next analyzed the microarray results of a cohort 
of 1809 patients with breast cancer [15]. Kaplan-Meier 
graphs for recurrence-free survival in the whole population 
or only in patients with luminal A, luminal B or basal-like 
breast cancer showed that high IL-17B expression was 
significantly correlated with poorer prognosis in the whole 
population (Figure 1D, p = 0.032 and 15% probability 
decrease) and in the basal-like subtype (Figure 1E, 
p = 0.019 and 15% probability decrease), but not in the 
other subtypes (Figure 1F and 1G). In contrast, high 
expression of IL-17A and IL-17E was associated with 
favorable outcomes in the whole population as well as 
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luminal A, luminal B or basal-like molecular subtypes 
(Supplementary Figure 1).
Importantly when we examined IL-17B expression 
on a human tissue array of breast cancer and metastasis, 
we found that IL-17B is mainly expressed by the tumor 
cells (Figure 2A). Reinforcing such observation, qRT-
PCR analysis of TILs expanded from 4 breast cancer 
patients’ biopsies showed that all the 4 samples were 
Figure 1: IL-17B/IL-17RB overexpression correlates with poor clinical outcome in patients with breast cancer. (A–C) 
Comparison of the overall survival and disease-free survival rate in a cohort of patients (n = 143) with breast cancer that express different 
levels of IL-17B (A), IL-17RB (B) or both IL-17B and IL-17RB (C) using the Kaplan-Meier method and the Wilcoxon test. (D–G) 
Prognostic effect of IL-17B expression in the whole population (D) and in patients with basal-like (E), luminal A (F) or luminal B (G) 
breast cancer assessed using the Kaplan-Meier method. Survival data were compared using the log-rank test. The third quartile was taken 
as the threshold for high IL-17B expression. Cohort size = 1809 patients, database 2012, collection of Affymetrix chips. 
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negative or limit to detection (TIL AL) for IL-17B mRNA 
expression, while half of them expressed IL-17A mRNA 
(Supplementary Figure 2).
On the contrary, analysis on a fresh breast tumor 
biopsy, by flow cytometry, revealed that IL-17RB was 
expressed by the EpCAM+ Cytokeratin+ tumor cells and by 
some fibroblasts, but also immune subpopulations within 
the tumor microenvironment (Figure 2B).  
IL-17B promotes resistance to paclitaxel in vitro 
via activation of the ERK pathway
We next investigated whether activation of the IL-
17B/IL-17RB pathway was involved in the development 
of resistance to conventional chemotherapeutic agents, 
such as paclitaxel, in breast tumors. Thus, various human 
breast cancer cell lines, in which IL-17RB expression was 
confirmed by flow cytometry (Figure 3A), were cultured 
in the presence of 10 ng/mL of recombinant human IL-
17B (rIL-17B) for 72 h and then incubated with paclitaxel 
at different concentrations. Pre-treatment with rIL-17B 
significantly decreased paclitaxel-induced cytotoxicity 
in BT20 and MDA-MB-468 cells (derived from TN/
basal-like breast cancers) and also in MCF7 cells (from 
a luminal A breast cancer) (Figure 3B), while it had not 
effect on the IL-17RB negative MDA-MB-435S cell 
line (Supplementary Figure 3A and 3B). Resistance 
to paclitaxel was strictly dependent on IL-17B/IL-
17RB interaction because addition of an anti-IL-17RB 
neutralizing antibody to the culture medium restored 
sensitivity to paclitaxel (Figure 3C). 
To elucidate the mechanisms involved in IL-17B-
induced resistance to paclitaxel, we first compared the 
kinase activation profile of BT20 cells cultured with 
or without rIL-17B using a phosphokinase antibody 
array. We identified several candidate proteins the 
activity of which was positively regulated by IL-
17B, such as AKT, STAT5a/b, ERK1/2 and MSK-
1/2 a downstream target of ERK1/2 (Figure 4A). 
Activation of the ERK1/2 pathway by rIL-17B was 
reminiscent to our previous observations with IL-17A, 
and we indeed confirmed that both cytokines induced 
similar ERK1/2 activity in BT20 cells as revealed by 
phosphorylation of ERK1/2 analyzed by western blotting 
using specific antibodies (Supplementary Figure 3C). 
Analysis of phosphorylation of ERK1/2 showed that, 
although the kinetics were not similar, ERK1/2 activity was 
consistently increased by rIL-17B in the three breast cancer 
cell lines BT20, MDA-MB-468 and MCF7, (Figure 4B), 
but not in the IL-17RB deficient MDA-MB-435S cell 
line (Supplementary Figure 3D). To further support the 
role of ERK1/2 activation in IL-17B-induced resistance 
to paclitaxel, we inhibited the ERK1/2 pathway in the 
three cell lines using PD98059, a chemical inhibitor 
of the MAPK/ERK cascade. PD98059 abrogated rIL-
17B-induced resistance to paclitaxel in MDA-MB-468 
and MCF7 cells (Figure 4C). Conversely, resistance to 
paclitaxel was only partially reverted in BT20 cells upon 
incubation with PD98059, suggesting the implication of 
a more complex signaling network in this cell line. For 
instance, we observed that rIL-17B also activated the 
NF-κB pathway in BT20 (Supplementary Figure 3E), 
but not in MCF7 and MDA-MB-468 cells. However, the 
pharmacological NF-κB inhibitors CAPE and BAY11-
7082, used at non-toxic concentrations, did not abrogate 
rIL-17B effect in BT20 cells. 
Real-time quantitative PCR analysis revealed that 
incubation with rIL-17B upregulated the expression of 
anti-apoptotic genes: BCL-2 in MDA-MB-468, BT20 and 
MCF7 cells, but also the two NF-κB-regulated genes BFL-
1 and BCL-XL [16, 17] in BT20 cells (Figure 4D). 
These observations suggest that IL-17B might exert 
a pro-tumoral activity in breast cancer by modulating 
paclitaxel efficacy through the activation of the ERK1/2 
pathway and upregulation of BCL-2 family members. 
IL-17B promotes resistance to paclitaxel in vivo
To evaluate IL-17B effect on resistance to paclitaxel 
in vivo, we xenografted nude mice with MCF7 or MDA-
MB-468 cells that express or not hIL-17B. In agreement with 
the absence of rIL-17B effect on MCF-7 and MDA-MB-468 
cell proliferation in vitro (Supplementary Figure 4A), 
constitutive IL-17B expression in MCF7-h-IL17B and 
MDA-MB-468-h-IL-17B cells did not have any effect 
on their expansion in vitro (Supplementary Figure 4B) 
and their tumor growth in vivo. Tumor size and growth 
kinetics were similar in nude mice engrafted with hIL-
17B expressing cells or control cells (Figure 5A and 5B). 
Paclitaxel treatment (10 mg/kg twice a week), when 
tumors reached a volume of about 100 mm3, induced 
tumor regression only in mice grafted with control cells, 
whereas the growth of MCF7-hIL-17B and MDA-MB-
468-hIL-17B tumors was not affected (Figure 5C and 5D). 
Moreover, administration of a neutralizing anti-IL-
17RB antibody (50 µg/injection twice a week) did not 
affect MCF7-hIL-17B and MDA-MB-468-hIL-17B 
tumor progression in the absence of paclitaxel treatment 
(Figure 5A and 5B). Conversely, it restored their sensitivity 
to paclitaxel, while the control isotype antibody had no 
effect (Figures 5C and 5D). Although there is no validated 
biomarker to predict resistance to taxanes in breast cancer, 
acquired resistance to paclitaxel in MCF-7 cells has been 
associated with BCL-2 upregulation. [18] In agreement, we 
observed that BCL-2 expression was significantly higher 
in tumors resistant to paclitaxel (mice xenografted with 
MCF7-h-IL17B cells) compared with sensitive tumors 
(mice xenografted with MCF-7 control cells, empty vector). 
Moreover, restoration of paclitaxel sensitivity in MCF7-h-
IL17B cells following the treatment with the anti-IL-17RB 
neutralizing antibody was associated with BCL-2 expression 
downregulation (Figure 5E). 
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Figure 2: Expression of IL-17B and IL-17RB in breast tumors. (A) Representative immunohistochemical staining of IL-17B 
expression in normal and breast cancer tissues. (B) Representative gating strategy and flow cytometry contour plots showing the percentages 
of IL-17RB expressing cells in a fresh dissociated breast tumor biopsy from a patient with invasive carcinoma. Percentages of IL17-RB+ 
cells were determined on CD45–Cytokeratin+EpCam+ tumor cells, CD45–Cytokeratin-Vimentin+ fibroblasts and within the CD45+ cells on 
CD4+ and CD8+ T cells, CD19+ B cells, CD33+ myeloid cells and CD56+ NK cells. 
Oncotarget6www.impactjournals.com/oncotarget
DISCUSSION
We demonstrated here that IL-17B, through binding 
to IL-17RB, promotes paclitaxel resistance in luminal and 
TN/basal-like breast cancer cells in vitro and in vivo and 
brought the first proof of concept that neutralization of the 
IL-17B/IL-17RB pathway could sensitize breast tumors to 
paclitaxel therapy. Together with the demonstration that 
IL-17RB signaling is associated with in vitro resistance 
to etoposide in breast cancer cell lines [12], our results 
indicate that the IL-17B/IL-17RB pathway can modulate 
the cytotoxic effect of drugs that act through at least two 
independent mechanisms: topoisomerase II inhibition 
(etoposide) and spindle poisoning (paclitaxel). As we 
previously reported for IL-17A [8], IL-17B present in the 
tumor microenvironment could be an important cancer 
cell survival factor and a mediator of therapy resistance in 
breast cancer. Interestingly, in contrast to IL-17A, which 
is produced by TILs, the main source of IL-17B in breast 
tumors seems to be tumor cells themselves and potentially 
Figure 3: IL-17B promotes resistance to paclitaxel in vitro. (A) Expression of IL-17RB BT20, MDA-MB-468 and cells MCF7 
determined by flow cytometry. (B) Percentages of drug-induced cell cytotoxicity in BT20, MDA-MB-468 and cells MCF7 cultured in 
FCS-free medium completed or not with 10 ng/mL rIL-17B for 24 h and treated with paclitaxel at concentrations ranging from 2.5 µg/mL 
to 40 µg/mL for 7 h. (C) Same as in B, except that cells were cultured in FCS-free medium completed or not with rIL-17B and/or anti-
IL-17RB antibody (10 µg/mL) before treatment with paclitaxel. The Student’s t-test was used to compare control and treatment groups; 
*p < 0.05 **p < 0.01 and ***p < 0.001.
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Figure 4: IL-17B-induced resistance to paclitaxel is mediated by activation of the ERK pathway. (A) Human phospho-
kinase array of BT20 cultured in the presence of medium alone or rIL-17B 10 ng/ml for 30 min. Red squares identify reference spot/
positive (full lane) and PBS/negative (dotted lane) controls. Arrows indicate proteins that are differentially phosphorylated between the 2 
conditions. (B) Western blot analysis of ERK1/2 phosphorylation (pErk) in BT20, MDA-MB-468 and cells MCF7 stimulated or not with 
10 ng/mL rIL-17B for different times. Total ERK and β-actin were used as protein loading control. Results are representative of at least 3 
experiments. (C)  Percentages of drug-induced cell cytotoxicity in BT20, MDA-MB-468 and cells MCF7 cultured in FCS-free medium 
completed or not with 10 ng/mL rIL-17B and/or 25 µM PD98059 (MAPK/ERK1/2 inhibitor) for 24 h before treatment with paclitaxel and 
treated with paclitaxel at concentrations ranging from 2.5 µg/mL to 40 µg/mL for 7 h. The Student’s t-test was used to compare control 
and treatment groups; *p < 0.05. (D) Expression of BCL2, BFL1 and BCL-XL mRNA in BT20, MDA-MB-468 and MCF7 cells stimulated 
with 10 ng/mL rIL-17B for 24 h. Values represent mean ± SD of 3 independent experiments; dashed line represents the level of expression 
of the target gene in untreated cells.
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Figure 5: IL-17B promotes resistance to paclitaxel in vivo. (A, B)  Tumor growth of MCF7 (A) and MDA-MB-468 (B) cells 
expressing hIL-17B (hIL-17B) or not (empty vector) treated with anti-IL-17RB antibody (αIL-17RB) or its isotype control (IgG2b) (50 
µg intratumor twice a week). Antibodies treatments were initiated when tumors reached about 100 mm3 in size. (C, D) Same as in A and B 
except that mice received also paclitaxel (10 mg/kg twice a week). Each group consisted of 10 mice, results are representative of at least 2 
experiments. (E)  BCL2 mRNA expression in MCF7 tumors at sacrifice (values for each individual mouse are indicated in the graph). The 
2-way ANOVA test and the corrected original False Discovery Rate (original method of Benjamini and Hochberg) multiple comparisons 
test were used to compare tumor growth in mice engrafted with MCF7 and MDA-MB-468 cells expressing hIL-17B treated with isotype 
control vs αIL-17RB and the Student’s t-test was used to compare mRNA expression; *p < 0.05 and ****p < 0.0001.
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fibroblasts, but not TILs (Figure 2 and Supplementary 
Figure 2). 
Huang et al. previously reported that disruption of 
the IL-17B/IL-17RB pathway in breast cancer cell lines 
negatively affects colony formation in soft agar assays. 
However, this effect was cell line-dependent, because 
IL-17B did not promote colony formation in cell lines 
that express low IL-17RB levels, such as MDA-MB-231 
cells.  Although we did not perform colony formation 
assays, we observed that rIL-17B has a cell line-dependent 
effect on breast cancer cell proliferation (Supplementary 
Figure 4A). Moreover, the absence of rIL-17B effect on 
MCF7 and MDA-MB-468 proliferation indicates that 
IL-17B promotion of chemotherapy resistance can be 
clearly dissociated from its effect on cell proliferation. 
These results are strengthened by the observation that 
cell proliferation was comparable in MCF7 and MDA-
MB-468 cells transfected with the hIL-17B-pcDNA3 
vector to express human IL-17B (MCF7-hIL-17B and 
MDA-MB-468-hIL-17B cells) and in MCF-7 and MDA-
MB-468 cells transfected with pcDNA3 vector alone 
(Supplementary Figure 4B). Conversely, MCF7-hIL-17B 
and MDA-MB-468-hIL-17B cells showed a high level 
of resistance to paclitaxel in vitro, comparable with the 
effect observed following incubation with rIL-17B in 
parental MCF7 and MDA-MB-468 cells (Supplementary 
Figure 4C). Altogether these results emphasize the specific 
effect of IL-17B on resistance of breast cancer cell lines to 
paclitaxel-based chemotherapy.
Our results could be important particularly for 
patients with TN breast cancer who cannot benefit from 
the current targeted therapies and whose initial clinical 
response to neoadjuvant chemotherapy determines 
their prognosis. The clinical relevance of IL-17B 
overexpression in the basal-like subtype is supported by 
microarray analyses showing poor relapse-free survival in 
patients with high IL-17B mRNA level. The observation 
that IL-17B effects were not limited to basal-like breast 
cancer cell lines suggests that the IL-17B/IL-17RB role in 
TN/basal-like breast tumors is mainly due to upregulation 
of this pathway rather than to TN/basal-like-specific 
mechanisms. However, the molecular mechanisms 
governing IL-17B expression upregulation in breast cancer 
cells or in their microenvironment are unknown and they 
deserve additional investigations. 
The basal-like subtype includes most (70–80%) TN 
breast tumors [19] that are not eligible for hormonotherapy 
and treatment with herceptin/trastuzumab. Although TN 
breast cancers are generally associated with poor outcome, 
they are not thought to be resistant to chemotherapy and 
anthracycline/taxane-based neoadjuvant chemotherapy 
is considered the standard-of-care regimen. With this 
treatment, pathological complete remission is obtained 
in about 22% of patients. However, early relapses are 
common and patients with TN breast cancer and residual 
disease are considered at high risk of recurrence and 
metastases [20, 21]. These clinical observations emphasize 
the importance of improving the initial response to 
chemotherapy by identifying and neutralizing resistance 
mechanisms. 
Finally, our results emphasize the role of the IL-17B/
IL-17RB signaling pathway in breast cancer and identify 
IL-17B and its receptor as attractive therapeutic targets 
for therapy. Nevertheless, the specific role of IL-17B 
compared with other IL-17 family members, especially IL-
17A, needs to be precisely investigated to develop adapted 
therapeutic strategies.   
MATERIALS AND METHODS
Breast cancer patients’ analysis
In the first cohort, overall survival (OS) and disease-
free survival (DFS) rates of breast cancer patients (n = 
143) that express different levels of IL-17B, IL-17RB 
or both IL-17B and IL-17RB were analyzed using the 
Kaplan-Meier method and the Wilcoxon test. Ethical 
approval was obtained from the Brotaf Health Authority 
(References 01/4046 and 01/4303) and all patients 
signed a written informed consent. In the second cohort, 
the prognostic effect of IL-17B expression in the whole 
population and in patients with luminal A, luminal B 
or with basal-like breast cancer was assessed using the 
Kaplan-Meier method. Survival data were compared using 
the log-rank test. The threshold of expression value giving 
the best RFS separation between high and low expression 
groups was first calculated, then the closest value among 
the median, tertiles and quartiles was retained as current 
threshold for analysis including each molecular subtype. 
The third quartile was taken as the threshold for high IL-
17B expression. Cohort size = 1809 patients, database 
2012, collection of Affymetrix chips (threshold 20). 
The median was taken as the threshold for high IL-17A 
expression. Cohort size = 1809 patients, database 2012, 
collection of Affymetrix chips (threshold 50). The median 
was taken as the threshold for high IL-17E expression. 
Cohort size = 1809 patients, database 2012, collection of 
Affymetrix chips (threshold 35). 
Cell culture and reagents
BT20, MCF7and MDA-MB-cell lines were obtained 
from ATCC. For all experiments, cells were cultured at 
37°C and 5% CO2. BT20 and MCF7 were cultured in 
RPMI supplemented with 10% heat-inactivated fetal 
calf serum (FCS), 2 mM L-glutamine and 40 µg/mL 
streptomycin. MDA-MB-468 were cultured in DMEM 
supplemented with 10% heat-inactivated FCS, 2 mM 
L-glutamine and 40 µg/mL streptomycin. All media and 
reagents were purchased from Invitrogen. Recombinant 
Human IL-17B (rIL-17B) (Peprotech) was used at a final 
concentration of 10 ng/mL, anti-IL-17B receptor antibody 
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(RD systems) at 10 µg/mL, MAPK/Erk-inhibitor PD98059 
(InvivoGen, San Diego, USA) at 25 µM. Paclitaxel was 
obtained from the Institut du Cancer de Montpellier and was 
used at a range of concentrations varying from 2.5 µg/mL 
to 40 µg/mL depending on cell lines. 
Clinical breast cancer biopsies
Human biopsy samples were obtained from the 
cancer center Institut Jean Godinot or from the Institut 
regional du Cancer de Montpellier. All patients were 
informed and agreed the study. Tumor was cut in small 
pieces of 0.5 cm3 in RPMI 1640 medium and dissociated 
by combining mechanical disruption (GentleMACSTM 
dissociator, Miltenyi Biotec) with enzymatic digestion 
using 500 µg/ml collagenase type IV- S (Sigma). After 
dissociation, sample was filtered (40 µm nylon filter) 
to remove any remaining larger particles from the cell 
suspension and the recovered cells were used immediately 
either for isolation and expansion of tumor-infiltrating 
lymphocyte (TIL) and cancer-associated fibroblasts as 
previously described [8] or for flow cytometry analysis.
Flow cytometry analysis
For flow cytometry analysis, cells were washed 
once with PBS and antibodies for surface markers were 
added at 4°C for 1 hour. When required, after washes 
cells were fixed and permeabilized, according to the BD 
Biosciences fixation and permeabilization procedures, 
and intracellular staining (vimentin and cytokeratin) was 
performed overnight at 4°C. Then, samples were washed, 
fixed in 1% PFA, and processed for data acquisition using 
a Cytoflex flow cytometer (Beckton Dickinson). Data were 
analyzed using the Flowjo 10 software. The following 
antibodies were used: anti-human CD45-BV786 (clone 
HI30, BD Horizon), anti-human CD19-FITC (clone 
HB19, Biolegend), anti-human CD56-PE (clone N901, 
Beckman Coulter), anti-human CD33-AF700 (clone 
WM53, BD Pharmingen), anti-human CD8-BV605 (clone 
SK1, BD Horizon), anti-CD4-BV650 (clone SK3, BD 
Horizon), anti-human EPCAM-PE-CF594 (clone EBA-1, 
BD Horizon), anti-human IL-17RB-APC (clone #170220, 
R&D Systems).
IL-17B immunohistochemistry
Tissue microarray (CBA4, Super Bio Chips, 
Clinisciences, Nanterre, France) was used to analyze the 
expression of IL-17B in breast tumors and in metastasis. 
The TMA sections were deparaffinized in xylene for 10 
min, rehydrated in an ethanol gradient and heated at 99°C 
for 30 min in citrate buffer (pH 9.0) for antigen retrieval. 
Endogenous peroxidase was inactivated by incubating the 
sections in 0.3% H2O2 for 20 min at room temperature. 
The sections were blocked in PBS-goat serum 20% for 
1 h at 37°C and incubated 1 h at room temperature with 
anti-IL-17B antibody (dilution, 1:50; LSB Bio, Seattle, 
US). Finally, the sections were stained with EnVision 
FLEX/HRP (Dako, Les Ulis, France) for 20 min at room 
temperature. Signal detection was carried out using a 
solution of DAB (vector SK4100; Vector laboratories, 
Burlingame, US). The TMA sections were counterstained 
with hematoxylin, dehydrated, and mounted.
Generation of stable cell lines over-expressing 
human IL-17B (hIL-17B)
The human IL-17B cDNA was subcloned into 
pcDNA3/hygromycin vector. MCF7 and MDA-MB-468 
cells were transfected with empty pcDNA3/hygromycin 
plasmid or with the hIL-17B-pcDNA3/hygromycin 
plasmid and selected with 225 µg/ml hygromycin B. The 
expression level of hIL-17B was confirmed by RT-qPCR. 
Isolation of mRNA and real-time quantitative 
PCR
Total RNA was isolated using the RNeasy Mini Kit 
(Qiagen, Courtaboeuf, France) and 1 μg of total RNA 
was reverse transcribed with SuperScript III (Invitrogen, 
Courtaboeuf, France) according to the manufacturer’s 
instructions. RT-qPCR analyses were performed using 
Sybr Premix Ex Tak (Tli RNase H plus, Takara Bio 
Europe/Clontech, Saint Germain en Laye, France) to 
determine the gene expression of IL-17A, IL-17B, IL-
17C, IL-17D, IL-17E, IL-17F, IL-17RA, IL-17RB, IL-
17RC, IL-17RD, IL-17RE, BCL2, BFL-1, BCL-XL and 
GAPDH with the following primers: IL-17A (Forward: 
5′-ACTACAACCGATCCACCTCAC-3′; Reverse: 5′-ACT 
TTGCCTCCCAGATCACAG-3′), IL-17B (Forward: 5′-GC 
CACTGGACCTGGTGTCACG-3′; Reverse: 5′-CTGGGG 
TCGTGGTTGATGCTGT-3′), IL-17C (Forward: 5′-TGC 
CAAGTGGGGGCAGGCTT-3′; Reverse: 5′-CGTGTCCA 
CACGGTATCTCCAGGG-3′), IL-17D (Forward: 5′-GC 
CCTGGGCCTACAGAATCTCCT-3′; Reverse: 5′-CCT 
CGGTGTAGACGGAACGGC-3′), IL-17E (Forward: 5′-T 
CCCCCTGGAGATATGAGTTGGACA-3′; Reverse: 5′-G 
GCATGGCCGCCGGTAGAAG-3′), IL-17F (Forward: 5′- 
TGGGCTCGATCAATGCTCAAGG-3′; Reverse: 5′-TCG 
ACCTCTTACTGCACACGG-3′), IL-17RA (Forward: 5′-T 
GCCCCTGTGGGTGTACTGGT-3′; Reverse: 5′-GCA 
GGCAGGCCATCGGTGTA-3′), IL-17RB (Forward: 5′-TA 
CCCCGAGAGCCGACCGTT-3′; Reverse: 5′-GGC 
ATCTGCCCGGAGTACCCA-3′), IL-17RC (Forward: 5′-G 
GCTTGGTTTCACGCGCAGC-3′; Reverse: 5′-CGGCC 
CTGCAAGAAGTCGGG-3′), IL-17RD (Forward: 5′-ACA 
CCTGTGGCTGGAGGGGAG-3′; Reverse: 5′-GCCAC 
TTGGTCATGGCAAGCA-3′), IL-17RE (Forward: 5′-C 
CACCTTCAGGCCATGCAGCC-3′; Reverse: 5′-CTGT 
CATCCGTGTGGGAGGCCA-3′), BCL2 (Forward: 5′-TG 
TGGATGACTGAGTACCTGAACC -3′; Reverse: 5′-GTT 
TGGGGCAGGCATGTTGAC-3′), BFL-1 (Forward: 
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5′-ACAGGCTGGCTCAGGACTATCT-3′; Reverse: 5′- 
CTCTGGACGTTTTGCTTGGAC-3′), BCL-XL (Forward: 
5′-CGTGGAAAGCGTAGACAAGGA-3′; Reverse: 5′-AT 
TCAGGTAAGTGGCCATCCAA-3′) and GAPDH (For—
ward: 5′-GAAGGTGAAGGTCGGAGTCA-3′; Reverse: 
5′-GACAAGCTTCCCGTTCTCAG-3′). Results were 
normalized to GAPDH housekeeping gene transcripts. 
Cytotoxicity assays
MCF7 (1,000 cells/well), BT20 and MDA-MB-468 
(3,000 cells /wells) cells were seeded in a 96 wells plate 
in adequate complete medium alone or with rIL-17B 
for 48 h. Then medium was removed and replaced with 
FCS-free medium supplemented or not with IL-17B, and/
or antibodies, and/or PD98059 when indicated for 24 h. 
Finally, cells were treated with paclitaxel at concentrations 
ranging from 2.5 µg/mL to 40 µg/mL, depending on the 
cell line, for 7 h. Untreated cells (control medium) and 
Triton X100 treated cells (100% cell death) were used 
as controls. Each condition was performed in triplicates. 
The cytotoxicity was determined using the Cytotoxicity 
Detection Kit (Roche) according to the manufacturer’s 
instructions. Percentage of cytotoxicity is calculated as 
followed: % = 100 * (exp value − control medium value)/
(Triton X100 treated cells value − control medium value).
Cell proliferation assays
MCF7, T47D, MDA-MB468m MDA-MB-436 (500 
cells/well) and BT20 (1,000 cells/well) cells were plated 
on 96-well plates and maintained for 24 h in complete 
medium. Medium was then removed and replaced with 
complete medium supplemented with or without rIL-
17B (Peprotech, Neuilly-sur-Seine, France). After 72 h of 
culture, cells were pulsed with 1 mCi of tritiated thymidine 
([3H]-TdR) per well. [3H]-TdR uptake was measured 
using PerkinElmer PerkinElmer MicroBeta2plate counter 
(PerkinElmer, Waltham, MA, USA). Each experiment was 
performed in hexaplicates.
MDA-MB-468 and MCF7 cells overexpressing 
or not human IL-17B were plated in E-plate 16 (ACEA 
Biosciences, San Diego, USA) of the Xcelligence system 
at 3,000 cells/well in complete medium. Once cells were 
attached to the bottom of the E-plate 16, cell proliferation 
was monitored every 3 h and up to 150 h. Cell proliferation 
was expressed as a cell index recorded using the RTCA 
software 2.0. The system displays the real-time growth 
curves of cells.
Phospho-kinase array 
BT20 breast cancer cells were serum starved for 24 h 
and then stimulated with rIL-17B (10 ng/mL) for 30 min. 
Then whole protein extracts were prepared and analyzed 
using the Human Phospho-Kinase Array Kit (ARY003B, 
R&D System) according to manufacturer’s instructions.
Immunoblotting
MCF7, BT20 and MDA-MB-468 breast cancer cells 
were serum-starved for 24 h and then stimulated with rIL-
17B (10 ng/mL). Whole protein extracts were prepared 
using the M-PER Mammalian Protein Extraction Reagent 
kit (Thermo scientific, Courtaboeuf, France) and analyzed 
by western blotting using antibodies against phosphorylated 
ERK1/2 (p-ERK) (1/500), ERK1/2 (ERK) (1/1000) or 
β-actin (1/10,000) (Cell signaling, Ozyme, Saint Quentin 
en Yvelynes, France). Signals were revealed using 
horseradish peroxidase-conjugated secondary antibodies 
(Jackson ImmunoResearch, Interchim, Montlucon, France) 
and enhanced chemiluminescence (ECL-Plus, Perkin Elmer, 
Courtaboeuf, France) according to the manufacturer’s 
instructions.
Xenografts in athymic nude mice
Eight-week-old female athymic nude Foxn1nu mice 
(Nude mice) were purchased from Envigo. MCF7 or 
MDA-MB-468 cells (2 × 106) with Matrigel (Matrigel 
matrix growth factors reduced, Corning, Bedford, USA) 
were injected subcutaneously into Nude mice. Tumor 
volumes were evaluated every 3 days after initial detection 
with a caliper. Intraperitoneal administration of taxol 
(10 mg/kg twice a week) or intra-tumoral injection of anti-
IL-17RB antibody or its isotype control IgG2b (50 µg 
per tumor in 20 µL of sterile PBS twice a week) was initiated 
when tumors reached about 100 mm3 in size. All procedures 
for animal handling and experiments were approved by the 
local animal facility “ComEth” Institutional Review Board 
under the supervision of the French LR Regional CEEA 
ethics committee on animal experimentation (Chairman: Pr 
M Michel, Montpellier, France).
Statistical analysis
Prism software version 7.0c (GraphPad Software, 
San Diego, CA) was used to analyze the data. For 
Figure 1, Kaplan-Meier survival curves were used to 
analyze the percentage survival of patients. For Figures 
2, 3, 4E and Supplementary Figure 2C, cytotoxicity and 
relative mRNA expression were assessed with the two-
tailed Student t-test.  In Figure 4, tumor growth curve 
comparisons were done using a 2-way ANOVA test and 
the corrected original False Discovery Rate (original 
method of Benjamini and Hochberg) multiple comparisons 
test. All data were presented as mean ± SEM except when 
indicated specifically in figure legends. The effect of rIL-
17B on cell proliferation (Supplementary Figure 2A) 
was assessed by the non-parametric Kruskal–Wallis test 
with Dunn’s post-test to compare treated vs untreated 
conditions. Statistical significance was indicated in figures 
with an asterisk where p < 0.05, two asterisks where 
p < 0.01 and three asterisks where p < 0.001 and four 
asterisks where p < 0.0001.
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